In a statement, Ro said, "We are working to ensure patients have access to the most effective medications available and will continue to follow all applicable FDA rules and guidelines." The supply update "starts the clock on having unfettered market access to the patented drug" for companies like Hims & Hers and the broader compounding GLP-1 space, analysts at Leerink Partners wrote in a note to clients Friday morning
Today, tirzepatide carries similar or identical warnings against severe side effects on its FDA labels
Anaesth Rep 2024;12:e12278.ArticlePubMedPMC 18
The side effect profiles of these medications reflect their distinct mechanisms of action and help guide patient selection
2 Medication options include Wegovy (semaglutide) 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg injection and 1.5 mg, 4 mg, 9 mg, and 25 mg pills, with Wegovy (semaglutide) 7.2 mg injection coming soon
Yes, pharmaceutical companies are developing additional dual and triple agonist medications